Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT00001174

Evaluation of the Genetics of Bipolar Disorder

This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

About this study

Study Description:

This project uses genetic mapping and whole exome sequencing methods to identify genetic markers and variations that contribute to the risk of bipolar disorder, an often severe, heritable condition affecting about one percent of the population. Individuals diagnosed with bipolar disorder are studied, along with their relatives. Phenotypic information obtained from clinical interviews and family history is correlated with genotypic information obtained from genetic marker and whole exome sequencing methods.

Objectives:

Primary Objective:

Identify genes involved in bipolar disorder and related conditions so that better methods of diagnosis, treatment, and prevention can be developed.

Secondary Objectives:

  • To identify genes that shape the clinical picture or influence response to treatment.
  • To replicate our findings in independent samples. Genome-wide genotyping, whole exome sequencing, demographic, and phenotype data will be requested under the usual dbGaP Data Access procedures and analyzed along with existing phenotypic and genetic data.
  • To analyze the clinical data, including but not limited to the diagnostic categories, in order to identify between-family differences which might identify genetically meaningful subgroups of families.
  • To submit coded phenotypes, genotypes, and DNA from informative families to a national archival database.
  • To establish a catalog of induced pluripotent stem cells suitable for functional genomic studies of neurons and glia in culture.

Endpoints:

Primary Endpoint:

The primary endpoint of this study is the identification of genes involved in risk for developing bipolar disorder.

Secondary Endpoints:

  • Pedigree structure, representing known relationships and reported mental health of first, second, and third-degree relatives
  • Dimensional data on mental health symptoms obtained from the Past History Schedule, Mood Disorders Questionnaire, and Symptom Checklist (SCL-90)
  • Cognitive data based on measures of executive function, working memory, attention, verbal memory, visuospatial reasoning, and affect recognition.
  • Lithium response data collected through the Retrospective Assessment of the Lithium Response (Alda) Scale
  • History of traumatic life events elicited with the Life Events Checklist for DSM-5 (LEC-5)
  • Genotype data obtained from SNP arrays or whole-exome sequencing
  • Skin biopsy or additional blood sample from selected participants
  • Induced pluripotent stem cells obtained from reprogramming of skin or blood cells.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged 18 years and over. Children are excluded for the following reasons: age at onset of BD is usually later than age 18, the diagnostic and assessment instruments we use are not validated in children.
  • In good general health as evidenced by medical history or diagnosed with or exhibiting symptoms of bipolar disorder or related conditions not attributable to substance abuse, or neurological disease; OR a 1st or 2nd degree relative of an enrolled participant. Related conditions are defined as those found more often among relatives of people with bipolar disorder or which have been shown to be genetically correlated with bipolar disorder through molecular genetic studies. These include major depression, schizophrenia, panic disorder, and attention deficit hyperactivity disorder.
  • Ability to safely provide a blood or saliva sample.
  • Ability of subject to understand and willingness to sign a written informed consent document.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Active alcohol or substance abuse.
  • Subjects who suffer cognitive impairment and are unable to provide an accurate psychiatric history are excluded since much of the diagnostic information relies on selfreport and recall of past events.

Treatment and study plan

Primary outcomes

  1. Diagnosis of bipolar disorder or related mental illness by direct interview

    Time frame: Diagnosis is established primarily at the initial study visit. Participants who consent to recontact are re-evaluated when they or family informants report events that could lead to a revised diagnosis.

    Psychiatric diagnosis is based on systematic review of established signs and symptoms, using an instrument designed to elicit retrospective information of known reliability, supplemented with information from family informants, any medical records, and by dimensional symptom measures.

Sponsors and collaborators

Lead sponsor

National Institute of Mental Health (NIMH)

Nih

Registry information

Official study title

Bipolar Genetics: A Collaborative Study

Important dates

Study start
1994
First posted
Nov 4, 1999
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.